Tarsus Pharmaceuticals (TARS) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vir Biotechnology (VIR) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 103.5% versus a gain of 7.6%. Over five years, TARS leads with a +158.1% price change compared with -70.5% for VIR. Tarsus Pharmaceuticals is the larger company by market cap ($3.34 billion vs $1.84 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TARS | VIR |
|---|---|---|
| Share price | $71.48 | $10.86 |
| Market cap | $3.34B | $1.84B |
| 1-day change | -2.90% | -5.77% |
| YTD return | -10.10% | +91.04% |
| 1-year return | +7.59% | +103.53% |
| 5-year return | +158.10% | -70.53% |
| EPS (TTM) | $-1.08 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $451.36M | — |
| Revenue growth (YoY) | +146.71% | — |
| Net income (latest FY) | $-66.42M | — |
| Operating margin | -15.72% | — |
| Net margin | -14.72% | — |
| 52-week high | $91.53 | $11.94 |
| 52-week low | $53.89 | $4.82 |
| Distance from 52-week high | -21.91% | -9.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +39.21% | +91.43% |
| Average volume | 894.35K | 1.90M |
| Shares outstanding | 46.79M | 169.22M |
| Employees | 370 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VIR has outperformed TARS by 95.9 percentage points over the past year.
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
TARS vs VIR FAQ
Which is bigger, Tarsus Pharmaceuticals or Vir Biotechnology?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.34B compared with $1.84B for Vir Biotechnology (VIR).
Which stock has performed better over the past year, TARS or VIR?
VIR returned +103.53% over the past 12 months, compared with +7.59% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Tarsus Pharmaceuticals and Vir Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.